Array's ‘extremely Compelling’ New Colon Cancer Data Spark Blockbuster Talk

The news that Array BioPharma’s clinical trial of its triplet therapy for colon cancer extended lives in a trial of patients with the BRAF mutation sent the company’s shares up 23% on Tuesday—a run that was no doubt driven by hopes the therapy will eventually be adopted as the standard of care in that population.

Source :

Array's ‘extremely compelling’ new colon cancer data spark blockbuster talk
Array BioPharma Says BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints
Will Bundled Measures Improve Diabetes Care?
Making Policy Work: The Lesson From Medicine
Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal
Small-Cap Biotechs Aim to Steal Spotlight at Cancer Meeting
Links for the Day: How Viola Davis Took Meryl Streep’s Oscar, President Apologies for Quran Burning, Killing the Food Truck Revolution, & More
News in November 2011
Array BioPharma Gets FDA Breakthrough Therapy Designation For BRAFTOVI